Context Urothelial carcinoma can exhibit a wide range of variant morphologies. Many
variants present diagnostic challenges and carry clinical implications that inform prognosis …

Context Variant histology of muscle-invasive (MIBC) and metastatic (mBC) bladder cancer
may define the cancer treatment modality and oncological outcomes. Objective To …

Muscle-invasive bladder cancers (MIBCs) are biologically heterogeneous and have widely
variable clinical outcomes and responses to conventional chemotherapy. We discovered …

BACKGROUND Neoadjuvant chemotherapy in pure urothelial bladder cancer provides a
significant survival benefit. However, to the authors' knowledge, it is unknown whether this …

Abstract The 2022 International Society of Urological Pathology (ISUP) Consensus
Conference on Urinary Bladder Cancer Working Group 2 was tasked to provide evidence …

Objectives To evaluate pathologic and survival outcomes among patients with variant
histology (VH) urothelial carcinoma of the bladder. Methods A retrospective review of an …

Adenocarcinoma is an uncommon malignancy in the urinary bladder which may arise
primarily in the bladder as well as secondarily from a number of other organs. Our aim is to …

Background Trimodality bladder-sparing therapy (TMT) is an acceptable treatment for
selected patients with muscle-invasive urothelial cancer. Outcomes of TMT in histologic …

Although approximately 80% of bladder cancer is caused by “conventional” urothelial
carcinoma (UC), the remaining 10% to 25% is the result of nonurothelial and “variants” of …

Purpose: There are conflicting reports on outcome trends following radical cystectomy (RC)
for bladder cancer. Materials and Methods: Evolution of modern bladder cancer …